Prostate Cancer Treatment
Learn about national guidelines and prostate cancer treatment options for people with inherited mutations.Stay up to date on research and information
Sign Up for FORCE NewslettersCancer Treatment
Treatment for cancer depends on the and grade of the disease based on pathology results. Tumor testing and genetic testing can provide additional clues about which treatments may work best for your cancer. For people with or advanced cancer, these additional tests are usually recommended.
Standard treatment may include a combination of surgery, radiation and hormone therapy. Some people may also benefit from treatment with chemotherapy, or . Clinical trials may be available for any of cancer.
People diagnosed with cancer who test positive for an in the genes below may have different treatment recommendations or options depending on their gene mutation.
Make sure that you receive a copy of your cancer test results, including your and your . Ask your doctor to explain your diagnosis, test results and treatment options in terms that you can understand. This will allow you to work with your doctor to choose the best treatment for you.
See below for more information on each of these cancer treatment topics.
In the News
![New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer](https://www.facingourrisk.org/cdn-cgi/image/width=500,height=330,fit=contain,format=webp/uploads/assets/xray/654d29470d76f.jpg)
Update: New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23) Este artículo está disponible en...
More Information on Cancer Treatment
Stages & Subtypes
Treatment for cancer depends on the and grade of the disease, which can be measured and reported in different ways. You can learn more in-depth information about how doctors and grade cancers.
Standard Therapies
Some prostate cancers may be small, slow-growing and require little or no treatment. Others may be large or more aggressive and require significant treatment. Read about standard treatment, which may include a combination of surgery, radiation, and hormonal therapies.
Genetic & Testing
Tumor testing and genetic testing can provide additional clues about which treatments may work best for your cancer.
Targeted & Immunotherapies
Targeted therapies are designed to attack or kill cancer cells, while sparing normal cells as much as possible. Immunotherapies are cancer treatments that help the body’s immune system detect and attack cancer cells.
Participate in Cancer Treatment Research
Below are some of our featured research studies looking at new treatments for cancer treatment. To search for more studies, visit our Search and Enroll Tool.
![PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness](https://www.facingourrisk.org/cdn-cgi/image/width=500,height=330,fit=contain,format=webp/uploads/assets/research/images/613779c8e84e0.jpg)
Clinicaltrials.gov identifier:
NCT04995198
![Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects](https://www.facingourrisk.org/cdn-cgi/image/width=500,height=330,fit=contain,format=webp/uploads/assets/research/images/622578046d6bb.jpg)
Clinicaltrials.gov identifier:
NCT04030559
![Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)](https://www.facingourrisk.org/cdn-cgi/image/width=500,height=330,fit=contain,format=webp/uploads/assets/research/images/6339001b54f8b.jpg)
Clinicaltrials.gov identifier:
NCT04038502
![Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib](https://www.facingourrisk.org/cdn-cgi/image/width=500,height=330,fit=contain,format=webp/uploads/assets/research/images/63e2c0cb19398.jpg)
Clinicaltrials.gov identifier:
NCT04550494
![Metastatic Castration Resistant Prostate Cancer Clinical Trial](https://www.facingourrisk.org/cdn-cgi/image/width=500,height=330,fit=contain,format=webp/uploads/assets/research/images/6421ce4d98b1c.jpg)
Metastatic Castration Resistant Prostate Cancer Clinical Trial
Clinicaltrials.gov identifier:
NCT03460977